Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy - Wikidata - wikimedia - TriplyDB

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

http://www.wikidata.org/entity/Q36089148

about

Modes of resistance to anti-angiogenic therapy Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy Tumor refractoriness to anti-VEGF therapy Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging Optimal combination of antiangiogenic therapy for hepatocellular carcinoma Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma Circulating biomarkers in advanced renal cell carcinoma: clinical applications Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer Lymphangiogenesis is required for pancreatic islet inflammation and diabetes Identification of novel therapeutic targets in microdissected clear cell ovarian cancers Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Tumor angiogenesis Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.Angiogenic inhibition in high-grade gliomas: past, present and future.Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group.A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer.Phase I study of pazopanib plus TH-302 in advanced solid tumors.Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy.Local acting Sticky-trap inhibits vascular endothelial growth factor dependent pathological angiogenesis in the eye.CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.Molecular mechanisms of resistance to tumour anti-angiogenic strategies Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Alterations in the intraocular cytokine milieu after intravitreal bevacizumab.Pharmacologic modulation of niche accessibility via tyrosine kinase inhibition enhances marrow and thymic engraftment after hematopoietic stem cell transplantation.Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells

P2860

Q24608005-86863BFC-41C2-4F3A-A2E0-EC6EA72268A2 Q24655930-44A32DD5-5990-42B1-A7F8-D6007E546E80 Q26747678-E3D3CF00-56D6-4D4C-971F-F967CE880125 Q26752752-DAC65F0B-AD5C-4F2C-9DAE-6176FEF9A5DD Q26773795-4058B333-180A-413D-B850-EDAF804B0441 Q26783895-549AE42F-313F-4F4D-B498-8194A4850E93 Q26799458-000C0B07-C237-420F-989B-D2C9B205D93F Q26823035-0541827A-C870-4E60-BD8F-43FD29377D03 Q26996793-D8877D90-AEDB-46DB-94CF-7FBA6D810E20 Q27016629-72DB0D37-08ED-4D96-848F-9CF0BEEC192A Q27021470-124105B5-4376-41F2-A9C6-BD64341AFA6B Q27023770-F0D8BE77-CAA6-441A-9CD3-3189B2EAB771 Q27320322-D3372BE1-147A-4796-BBD9-3DCE3CE3E8F2 Q28742322-285FA5DF-F5E9-40A8-BFBC-130DEDEE90D5 Q28742873-F92D85DE-3C51-4819-B1A6-0A7FF4F7DB31 Q29614537-29DFB17E-D06F-475E-BAB2-EA311A976A45 Q29614938-9A31BE02-3A17-41BB-A9D0-68623E33436A Q30438696-4A4D741D-A254-46A4-8EEB-603F49FC9314 Q30455596-DC7B8DF0-6D33-4866-A170-27C057C6488C Q30455612-F50C3CD0-A4D5-40C4-9C9D-706230B12937 Q33394774-26EE4592-FCD4-471E-9CEC-A574A0149B7E Q33405318-951E9207-46CD-4C25-A3CC-21C6EB92A263 Q33410375-F6FAF2CF-1E59-418C-88AA-719E197994BA Q33424257-D246CC4C-5790-409D-BCC7-E40B6DCC412C Q33429309-D6CA7229-A9EB-418B-951E-D9D42EF782DB Q33439635-7774279A-6E92-4A55-BE4D-1D5CD2340B77 Q33457195-F432742E-740B-42DE-B851-9FE020BD1C4C Q33616649-DE4EBCB6-AB12-4390-91D9-4703A72F8F32 Q33623357-D6E9E481-9D5B-4787-97BF-DB34BFE88986 Q33630819-843213FA-3993-43A2-B2E0-5169E7D925B7 Q33718025-387EDD1B-310F-47D4-B061-60ED4B6F439C Q33770680-9A4DBEDB-A6AC-40F5-BEBF-4FBF598AA2B8 Q33845524-43C38F6D-FD9E-4773-A48D-D5345002FC46 Q33871518-F3D1DD05-D75A-47A0-82F0-93E32C61B365 Q33899627-89D3D8F4-10A6-4F22-9207-B189EAFC28FD Q34080323-E35F654B-40F5-455D-B33B-04EAA6D6115B Q34340390-6B6001B4-36A5-446D-8103-DF7ED298FD66 Q34356881-77ADB54B-4039-4F54-8A53-6D4B8A0ABA98 Q34468729-29CBD126-5294-45D3-8D23-FD1E1125D6AD Q34471954-FEB73BAC-CD3D-422C-A7DA-0E6876172EB7

P2860

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

http://www.wikidata.org/entity/Q36089148

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Multiple circulating proangiog ...... relate with antitumor efficacy

@ast

Multiple circulating proangiog ...... relate with antitumor efficacy

@en

type

label

Multiple circulating proangiog ...... relate with antitumor efficacy

@ast

Multiple circulating proangiog ...... relate with antitumor efficacy

@en

prefLabel

Multiple circulating proangiog ...... relate with antitumor efficacy

@ast

Multiple circulating proangiog ...... relate with antitumor efficacy

@en

P1433

Q36089148-EAF56699-470E-4160-906B-8E0B1C5DA34A

P1476

Q36089148-F8DF8E25-2458-4CC4-8A66-29014F567E0E

P2093

Q36089148-331EE629-B859-47AB-ACCB-1055F9D73F43

Q36089148-38873934-5F97-4E89-925C-CF704E2AC4EE

Q36089148-3A10417F-3C75-449A-886A-CB8E66AA2BA5

Q36089148-8FF7E1D8-9F48-4F93-A832-C4C56A845A5A

P2860

Q36089148-0AC7E2A0-8790-4C3C-B2FF-862086CF216A

Q36089148-117C8F67-9FFD-439A-BA5E-40430BCBC42B

Q36089148-1DB0CF86-FE49-4380-8A14-9B972881015C

Q36089148-1DF8D4B6-DD7E-4B12-9AEF-212EDD4D5751

Q36089148-240AD911-CDB2-4A88-9F79-17C76B2FCBED

Q36089148-240B0EB3-8BEE-46F1-9663-5D3A870277E0

Q36089148-25A56C8C-A753-4C76-A003-C193C10DEC59

Q36089148-340BE57A-C802-424C-8882-871B8423BFD9

Q36089148-5FF95A82-26EC-4FAF-B6B3-48C7C5DBDC2E

Q36089148-753BFB22-CDCA-4ACE-80B0-ACFE9C747FC4

P304

Q36089148-0CC8EAF3-B0F0-4AD9-BBA5-6167FD5E3263

P31

Q36089148-9451741C-AA3D-4CDC-8D79-718BA6DC6631

P356

Q36089148-5EEEE9EC-0154-499E-B34A-174914EAF925

P407

Q36089148-BE0B64A7-4BA1-4486-9F52-32C3EA17E4CA

P433

Q36089148-F700A407-8E75-4008-940A-F455E4E085A9

P478

Q36089148-5BB284D6-E2F8-4DF0-B1A9-6178FCC56929

P50

Q36089148-1E1753DD-A6F9-4AAE-9742-2E5A2CD31E2E

P577

Q36089148-BCE5D2AB-D83A-42FF-AAD1-2FDC3C932C97

P5875

Q36089148-0D10C9C0-0360-4C3E-969B-E9F4B45AFFBF

P698

Q36089148-EE9ACE0D-241E-4E8F-9607-9D3B069934BB

P932

Q36089148-BA3FAD35-FA55-4735-A494-4586BA9ABD84

P356

PNAS.0708148104

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Multiple circulating proangiog ...... relate with antitumor efficacy

@en

P2093

Anthony J Mutsaers

http://www.w3.org/2001/XMLSchema#string

Christina R Lee

http://www.w3.org/2001/XMLSchema#string

James G Christensen

http://www.w3.org/2001/XMLSchema#string

Robert S Kerbel

http://www.w3.org/2001/XMLSchema#string

P2860

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.

Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.

Stromal cell-derived factor-1 enhances pro-angiogenic effect of granulocyte-colony stimulating factor.

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Rapid vascular regrowth in tumors after reversal of VEGF inhibition.

Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue.

Reanalysis of cancer drugs: old drugs, new tricks.

Endothelial progenitor cells: characterization and role in vascular biology.

Regulation of angiogenesis by hypoxia-inducible factor 1.

P304

17069-17074

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0708148104

http://www.w3.org/2001/XMLSchema#string

P407

P433

43

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5902306

http://www.w3.org/2001/XMLSchema#string

P698

17942672

http://www.w3.org/2001/XMLSchema#string

P932

2040401

http://www.w3.org/2001/XMLSchema#string